ESSA Pharma Inc. (EPIX)

NASDAQ: EPIX · Real-Time Price · USD

1.890

+0.010 (0.53%)

At close: Aug 1, 2025, 4:00 PM

1.870

-0.020 (-1.04%)

After-hours: Aug 1, 2025, 7:18 PM EDT

0.53% (1D)

Market Cap	83.36M
Revenue (ttm)	n/a
Net Income (ttm)	-28.50M
Shares Out	44.34M
EPS (ttm)	-0.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,036
Open	1.890
Previous Close	1.880
Day's Range	1.890 - 1.890
52-Week Range	1.400 - 7.880
Beta	1.56
Analysts	Hold
Price Target	2.00 (+5.82%)
Earnings Date	Aug 12, 2025

About ATVI

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 35

Stock Exchange NASDAQ

Ticker Symbol EPIX

Website https://www.essapharma.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for EPIX stock is "Hold." The 12-month stock price target is $2.0, which is an increase of 5.82% from the latest price.

Price Target

$2.0

(5.82% upside)

Analyst Consensus: Hold

Stock Forecasts

News

ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 23, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announc...

11 days ago - PRNewsWire

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif.

Other symbols: XOMA

20 days ago - PRNewsWire

ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," o...

3 months ago - PRNewsWire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit - EPIX

NEW YORK , March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class ...

4 months ago - PRNewsWire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options

5 months ago - GlobeNewsWire

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada , March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of ...

5 months ago - PRNewsWire

Shareholders of ESSA Pharma Inc. Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - EPIX

NEW YORK , Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class p...

5 months ago - PRNewsWire

ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ...

6 months ago - PRNewsWire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit – EPIX

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX).

6 months ago - GlobeNewsWire

ESSA Pharma Inc. Is Being Sued For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ESSA Pharma Inc. ("ESSA" ...

6 months ago - Accesswire

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options

6 months ago - GlobeNewsWire

Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of securities of ESSA Pharma Inc. ...

6 months ago - Business Wire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 17, 2024 /PRNewswire/ - ESS...

8 months ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:E...

9 months ago - Accesswire